试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)
编号:NCT01009294登记状态:提前终止企业 / 申办者:PTC Therapeutics
药物 / 成分:Ataluren、Chronic Corticosteroid Therapy
登记的停止原因(原文):Terminated early because a similar study with Ataluren exhibited lack of efficacy at the high dose (not due to safety concerns).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
编号:NCT01053507登记状态:提前终止企业 / 申办者:Cady, Roger, M.D.
药物 / 成分:sumatriptan/naproxen sodium、Placebo
登记的停止原因(原文):Enrollment rate was slower than anticipated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
编号:NCT01249443登记状态:提前终止企业 / 申办者:AIDS Malignancy Consortium
药物 / 成分:vorinostat、diagnostic laboratory biomarker analysis、pharmacological study、carboplatin
登记的停止原因(原文):Inadequate accrual rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour
编号:NCT02292771登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Retosiban、Atosiban、Placebo matching retosiban、Placebo matching atosiban
登记的停止原因(原文):The study was stopped due to the feasibility of recruiting the study in a timely manner
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome
编号:NCT02394106登记状态:提前终止企业 / 申办者:Istituto Giannina Gaslini
药物 / 成分:Ofatumumab、Placebo
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Acute Effects of Inhaled Treprostinil in Fontan Patients
编号:NCT02769624登记状态:提前终止企业 / 申办者:Children's Hospital Medical Center, Cincinnati
药物 / 成分:Treprostinil、Placebo
登记的停止原因(原文):Study was stopped early due to inability to recruit additional participants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
编号:NCT03511222登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Vorolanib、Nivolumab、Pembrolizumab
登记的停止原因(原文):Low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-28
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
编号:NCT00712270登记状态:提前终止企业 / 申办者:Kettering Health Network
药物 / 成分:Aripiprazole、Risperidone
登记的停止原因(原文):Study terminated due to failure to meet sufficient enrollment for valid analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-28
A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor
编号:NCT02377466登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Retosiban IV infusion、Placebo IV infusion
登记的停止原因(原文):Asset terminated by PIB
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-28
Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
编号:NCT02507232登记状态:提前终止企业 / 申办者:Santosh Kesari
药物 / 成分:NovoTTF-200A、Temozolomide
登记的停止原因(原文):low enrollment
查看官方原始记录 ↗